Official ESCRS | European Society of Cataract & Refractive Surgeons
Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Posters

Search Title by author or title

Primary pterygium surgery: make it simple if it is simple

Poster Details

First Author: M. Mendez Ramos SPAIN

Co Author(s):    P. Maqueda Gonzalez                    

Abstract Details

Purpose:

To document recurrence rate after surgery of primary pterygium with simple resection and displacement of conjunctival flaps and to compare our recurrence rate with that reported for primary pterygium surgery with bare scleral tecnique.

Setting:

Patients included for primary pterygium surgery in Hospital de Cáceres (Spain), from September 2013 to June 2014.

Methods:

Retrospective descriptive observational study of forty-three patients diagnosed of primary pterygium, grades T1 to T3. All surgeries were performed by the same surgeon. The patients were followed for 18 months. Postoperatively, the patients received topical dexamethasone and ketorolac tromethamine.Recurrence rate was documented and compared with recurrence rates reported in recent medical literature for primary pterygium surgery with bare scleral technique.

Results:

Only two patients showed some grade of recurrence (4.6%). Of the patients with recurrence, one have some grade of limbal insufficiency documented previously to surgery and the other was diagnosed retrospectively as a pseudopterygium. Medium surgery time was 14 min (11-16 min).

Conclusions:

Surgery of primary pterygium with simple resection plus displacement of conjunctival flaps is a simple technique with good results in selected patients. This technique avoids the risks of excessive conjunctival manipulation and the use of biological fibrin glue. Treatments should be proportional to the severity of the pathology treated, avoiding overtreatment.

Financial Disclosure:

NONE

Back to Poster listing